Jean-Louis Escary
Plus aucun poste en cours
Profil
Jean-Louis Escary was the founder and had founded GenOdyssee SA in 1999, where he held the titles of Chairman & Chief Executive Officer from 2009 to 2011.
He also worked as the Chief Business Development Officer at PolTREG SA. Dr. Escary received a doctorate degree from Université Pierre et Marie Curie in 1994.
Anciens postes connus de Jean-Louis Escary
| Sociétés | Poste | Fin |
|---|---|---|
| POLTREG S.A. | Corporate Officer/Principal | 21/02/2024 |
GenOdyssee SA
 GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of 'next generation' protein products for already developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins. | Fondateur | 11/05/2011 |
Formation de Jean-Louis Escary
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| POLTREG S.A. | Health Services |
| Entreprise privées | 2 |
|---|---|
GenOdyssee SA
GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of 'next generation' protein products for already developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins. | Commercial Services |
| Université Pierre et Marie Curie | Consumer Services |
